GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of tried cagrilintide for 8 weeks. here is what happened. — 35 comments in the full submission. View in context.
2.7k
c/cagrilintide·submitted 1 year ago by u/sten_rautio

tried cagrilintide for 8 weeks. here is what happened.

Trial Databranch of 11 comments

Posting this because I searched for it and got nothing useful. Setup: 2.4mg, week 57, constipation present but not ruining anything. I changed exactly one variable — satiety — and tracked it for 20 weeks. Result: a difference, but a small one, and well inside what I would call noise if someone else posted it. So I am…

Read the full submission and all 35 comments →

This branch

11 comments, started 1 year ago
u/ravi_sandvik228 points·1 year ago

Yeah, amylin is doing different work than GLP-1.

replysharereportpermalink
u/sten_rautioOP135 points·1 year ago

I am going to push back on this slightly.

replysharereportpermalink
u/b12_baseline86 points·1 year ago

the amylin agonist pool is small, community is amylin

replysharereportpermalink
u/wrong_network_w29 points·1 year ago

REDEFINE readouts are phase 22 data

replysharereportpermalink
u/zeynep_zielinski51 points·1 year ago

long-acting amylin is CagriSema, different satiety profile

replysharereportpermalink
u/tomas_kimani101 points·1 year ago

amylin is not a GLP-1, posts conflating them get corrected

replysharereportpermalink
u/ferritin_low64 points·1 year ago

research use only, no human protocols in posts

replysharereportpermalink
u/sten_rautioOP48 points·1 year ago

Strongly agree. REDEFINE is phase 16, not final.

replysharereportpermalink
u/ice_pack_auditcold chain76 points·1 year ago

This is correct. The co-agonism is real.

replysharereportpermalink
u/emil_agyeman97 points·1 year ago

the mechanism is different, the side effect profile reflects it

replysharereportpermalink
u/nadia_bakker50 points·1 year ago

the mechanism is different, the side effect profile reflects it

Disagree on that part. 99.2% and 98.9% on the same vial is normal.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →